https://www.nasdaq.com/press-release/allakos-announces-topline-phase-3-data-from-the-enigma-2-study-and-phase-2-3-data
https://www.nasdaq.com/press-release/allakos-announces-expansion-of-lirentelimab-development-into-atopic-dermatitis
https://www.nasdaq.com/press-release/allakos-provides-business-update-and-reports-third-quarter-2021-financial-results
https://www.nasdaq.com/press-release/allakos-presents-data-at-acg-2021-from-prospective-study-showing-high-prevalence
https://www.nasdaq.com/press-release/allakos-announces-multiple-presentations-related-to-eosinophil-and-mast-cell-driven-3
https://www.nasdaq.com/press-release/allakos-provides-business-update-and-reports-second-quarter-2021-financial-results
https://www.nasdaq.com/press-release/allakos-completes-patient-enrollment-in-phase-3-eosinophilic-gastritis-and-or
https://www.nasdaq.com/press-release/new-allakos-data-presented-at-ddw-2021-suggest-that-eosinophilic-gastritis-and-or
https://www.nasdaq.com/press-release/allakos-reports-first-quarter-2021-financial-results-and-provides-business-update
https://www.nasdaq.com/press-release/allakos-appoints-baird-radford-as-chief-financial-officer-2021-04-19
https://www.nasdaq.com/press-release/allakos-announces-multiple-presentations-related-to-eosinophil-and-mast-cell-driven-2
https://www.nasdaq.com/press-release/allakos-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/allakos-appoints-natalie-holles-to-its-board-of-directors-2020-12-22
https://www.nasdaq.com/press-release/allakos-reports-third-quarter-2020-financial-results-and-provides-business-update
https://www.nasdaq.com/press-release/allakos-announces-presentation-from-its-eosinophilic-gastrointestinal-diseases
https://www.nasdaq.com/press-release/allakos-announces-pricing-of-public-offering-of-common-stock-2020-10-28
https://www.nasdaq.com/press-release/allakos-previews-preliminary-financial-results-for-the-three-months-ended-september
https://www.nasdaq.com/press-release/allakos-announces-proposed-public-offering-of-common-stock-2020-10-27
https://www.nasdaq.com/press-release/allakos-announces-results-from-a-phase-1-study-of-subcutaneously-administered
https://www.nasdaq.com/press-release/results-from-prospective-prevalence-study-indicate-that-eosinophilic-gastritis-and
https://www.nasdaq.com/press-release/allakos-announces-publication-of-results-from-the-phase-2-study-of-lirentelimab-ak002
https://www.nasdaq.com/press-release/allakos-reports-second-quarter-2020-financial-results-and-provides-business-update
https://www.nasdaq.com/press-release/allakos-initiates-patient-recruitment-for-ak002-registrational-studies-2020-06-03
https://www.nasdaq.com/press-release/allakos-announces-multiple-presentations-related-to-eosinophil-and-mast-cell-driven-1
https://www.nasdaq.com/press-release/allakos-announces-a-presentation-of-antolimab-in-patients-with-severe-allergic
https://www.nasdaq.com/press-release/allakos-reports-first-quarter-2020-financial-results-2020-05-11
https://www.nasdaq.com/press-release/allakos-announces-positive-interim-results-from-an-open-label-extension-study-of
https://www.nasdaq.com/press-release/allakos-announces-multiple-presentations-related-to-eosinophil-and-mast-cell-driven-0
https://www.nasdaq.com/press-release/allakos-announces-positive-phase-1-results-with-antolimab-ak002-in-mast-cell
https://www.nasdaq.com/press-release/allakos-announces-the-initiation-of-antolimab-ak002-clinical-studies-2020-03-24
https://www.nasdaq.com/press-release/allakos-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides
https://www.nasdaq.com/press-release/allakos-announces-multiple-presentations-related-to-eosinophil-and-mast-cell-driven
https://www.nasdaq.com/press-release/shareholder-alert%3a-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-58
https://www.nasdaq.com/press-release/hagens-berman-national-trial-attorneys-urges-allakos-allk-investors-with-significant
https://www.nasdaq.com/press-release/allk-losses-alert%3a-bernstein-liebhard-llp-reminds-investors-of-its-investigation-of
https://www.nasdaq.com/press-release/allakos-reports-third-quarter-2019-financial-results-2019-11-12
